A 12-Week, Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of FerShizn on Improving Body Fat of Overweight or Obesity Subject.

utracore0 个研究点目标入组 100 人开始时间: 待定最近更新: 2023年12月19日

适应症

试验速览

暂无简介。

•Inclusion Criteria:
•1. Male and female subjects, 19-60 years of age
•2. BMI of 23-30 kg/m2
•3. Willing and able to provide signed and dated informed consent prior to any study-related procedures and willing and able to comply with all study procedures

•Exclusion Criteria:
•1) Stable body weight by subject report (+ 5%) in the previous 3 months prior to Screening
•2) Anti-obesity (energy metabolism, appetite suppression, weight control, body fat decomposition, carbohydrate blocking and gastrointestinal activity modifiers such as fat absorption inhibition) drugsm traditational medicines, and diet supplement (including probiotics) the previous 6 months prior to Screening (reference to Prohibited Concomitant Substances)
•3)the purpose of improving cholesterol and blood circulation drugs or diet supplement previous 3 months prior to Screening
•4) physical examination and clinical examination have liver disorder , kidney disorder, pancreas disorder , biliary tract disorder , cardiovascular system disorder , respiratory system disorder , endocrine system disorder , and central nervous system disorders or malignant tumor (however, more than 5 years after surgery Participation is possible if it does not recur)
•5)Those who have or have experience antipsychotic medication and psychotherapy for depression or other mental disorders
•6)Those who have a medical history of clinically significant hypersensitivity reactions or have a possibility of hypersensitivity to raw materials and similar functional food of products for human application testing

发起方

utracore